Skip to main content
Top
Published in: International Journal of Colorectal Disease 5/2004

01-09-2004 | Original Article

Surgical management of entero and colocutaneous fistulae in Crohn’s disease: 17 year’s experience

Authors: Lisa S. Poritz, G. Alessandra Gagliano, Robin S. McLeod, Helen MacRae, Zane Cohen

Published in: International Journal of Colorectal Disease | Issue 5/2004

Login to get access

Abstract

Background and aims

Fistulous disease is common in Crohn’s disease, and entero- and colocutaneous fistulae are particularly debilitating and difficult to manage. We present the results of surgical management of these fistulas.

Patients and methods

Retrospective chart review of all 51 patients with Crohn’s disease (56 surgical procedures) undergoing surgery for cutaneous fistulae between 1983 and 2000.

Results

Previous surgery for Crohn’s disease had been carried out in 43 patients (84%). The fistula site was enterocutaneous in 36 patients (64%), colocutaneous in 12 (21%), and anastomotic in 8 (14%); 9 patients (16%) also had associated enteroenteric fistulas. The onset of the fistula followed abscess drainage in 15 (27%) and occurred at the site of recurrent disease in 41 (73%). Forty patients (71%) initially underwent conservative management prior to surgery; 16 (28%) underwent surgery directly. Surgical procedures were: 25 ileocolic resections, 8 stoma revisions with resection, 8 small bowel resections 7 subtotal colectomies, 4 partial colectomies, 3 proctocolectomies, and one fistula tract excision. Mean total length of stay was 18 days (postoperative 10.7 days). Six (11%) patients had eight postoperative complications. Mean follow-up was 48.6 months (range 3–187). Recurrence as defined by either clinical examination or reoperation was documented in nine fistulas (16%), with a mean time to recurrence of 27 months.

Conclusion

Entero-and colocutaneous fistulae usually occur from a site of active disease. Surgical management with bowel resection, including the fistula, is the preferred method of treatment. Morbidity has been low and recurrence rate lower than expected.
Literature
1.
go back to reference Tassiopoulos AK, Baum G, Halverson JD (1996) Small bowel fistulas. Surg Clin North Am 76:1175–1181PubMed Tassiopoulos AK, Baum G, Halverson JD (1996) Small bowel fistulas. Surg Clin North Am 76:1175–1181PubMed
2.
go back to reference Berry SM, Fischer JE (1994) Enterocutaneous fistulas. Current Prob Surg 31:474–566CrossRef Berry SM, Fischer JE (1994) Enterocutaneous fistulas. Current Prob Surg 31:474–566CrossRef
3.
go back to reference Elson CO, Iqbal N (2001) Options in managing enteral fistulae in inflammatory bowel disease. In: Bayless TM, Hanauer SB (eds) Advanced therapy of inflammatory bowel disease, 1st edn. Decker, Hamilton, pp 401–404 Elson CO, Iqbal N (2001) Options in managing enteral fistulae in inflammatory bowel disease. In: Bayless TM, Hanauer SB (eds) Advanced therapy of inflammatory bowel disease, 1st edn. Decker, Hamilton, pp 401–404
4.
go back to reference Fazio VF, Coutsoftides T, Steiger E (1983) Factors influencing the outcome of treatment of small bowel cutaneous fistula. World J Surg 7:481–488PubMed Fazio VF, Coutsoftides T, Steiger E (1983) Factors influencing the outcome of treatment of small bowel cutaneous fistula. World J Surg 7:481–488PubMed
5.
go back to reference Fischer JE (1977) Hyperalimentation. Adv Surg 11:1 Fischer JE (1977) Hyperalimentation. Adv Surg 11:1
6.
go back to reference Hill GL, Bourcheir RG, Witney GB (1988) Surgical and metabolic management of patients with external fistulas of the small intestine associated with Crohn’s disease. World J Surg 12:191–197PubMed Hill GL, Bourcheir RG, Witney GB (1988) Surgical and metabolic management of patients with external fistulas of the small intestine associated with Crohn’s disease. World J Surg 12:191–197PubMed
7.
go back to reference O’Dwyer ST (1997) Enterocutaneous fistula: conservative and surgical management. In: Allan RN, Rhodes JM, Hanauer SB, Keighley MRB, Alexander-Williams J, Fazio VF (eds) Inflammatory bowel diseases, 3rd edn. Churchill Livingstone, New York, pp 883–893 O’Dwyer ST (1997) Enterocutaneous fistula: conservative and surgical management. In: Allan RN, Rhodes JM, Hanauer SB, Keighley MRB, Alexander-Williams J, Fazio VF (eds) Inflammatory bowel diseases, 3rd edn. Churchill Livingstone, New York, pp 883–893
8.
go back to reference Hawker PC, Givel JC, Keighley MRB, Alexander-Williams J, Allan RN (1983) Management of enterocutaneous fistulae in Crohn’s disease. Gut 24:284–287PubMed Hawker PC, Givel JC, Keighley MRB, Alexander-Williams J, Allan RN (1983) Management of enterocutaneous fistulae in Crohn’s disease. Gut 24:284–287PubMed
9.
go back to reference Present DH (1999) Review article: the efficacy of infliximab in Crohn’s disease-healing of fistulae. Aliment Pharmacol Ther 13:23–28CrossRefPubMed Present DH (1999) Review article: the efficacy of infliximab in Crohn’s disease-healing of fistulae. Aliment Pharmacol Ther 13:23–28CrossRefPubMed
10.
go back to reference Jakobovits J, Schuster MM (1984) Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 79:533–540 Jakobovits J, Schuster MM (1984) Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 79:533–540
11.
go back to reference Korelitz BI, Present DH (1985) Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci 30:58–64PubMed Korelitz BI, Present DH (1985) Favorable effect of 6-mercaptopurine on fistulae of Crohn’s disease. Dig Dis Sci 30:58–64PubMed
12.
go back to reference Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS (1980) Treatment of Crohn’s disease with 6-mercaptopurine a long-term, randomized, double-blind study. N Engl J Med 302:981–987PubMed Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS (1980) Treatment of Crohn’s disease with 6-mercaptopurine a long-term, randomized, double-blind study. N Engl J Med 302:981–987PubMed
13.
go back to reference Hanauer SB, Smith MB (1993) Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporine A. Am J Gastroenterol 88:646–649PubMed Hanauer SB, Smith MB (1993) Rapid closure of Crohn’s disease fistulas with continuous intravenous cyclosporine A. Am J Gastroenterol 88:646–649PubMed
14.
go back to reference Knight DM, Trinh H, Le J et al (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443–1453CrossRefPubMed Knight DM, Trinh H, Le J et al (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443–1453CrossRefPubMed
15.
go back to reference Targan SR, Hanauer SB, van Deventer SJH et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor (alpha) for Crohn’s disease. N Engl J Med 337:1029–1035PubMed Targan SR, Hanauer SB, van Deventer SJH et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor (alpha) for Crohn’s disease. N Engl J Med 337:1029–1035PubMed
16.
go back to reference Van Dullemen HM, van Deventer SJH, Hommes DW et al (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129–135PubMed Van Dullemen HM, van Deventer SJH, Hommes DW et al (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129–135PubMed
17.
go back to reference Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405PubMed Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405PubMed
18.
go back to reference Rutgeerts P, D’Haens G, Targan S et al (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117:761–769PubMed Rutgeerts P, D’Haens G, Targan S et al (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117:761–769PubMed
19.
go back to reference Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ (2001) Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 96:722–729CrossRefPubMed Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ (2001) Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 96:722–729CrossRefPubMed
20.
go back to reference McCabe RP, Woody J, van Deventer SJH et al (1996) A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn’s disease. Gastroenterology 110:A962 McCabe RP, Woody J, van Deventer SJH et al (1996) A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn’s disease. Gastroenterology 110:A962
21.
go back to reference McIntyre PB, Ritchie JK, Hawley PR, Bartram CI, Lennard-Jones JE (1984) Management of enterocutaneous fistulas: a review of 132 cases. Br J Surg 71:293–296PubMed McIntyre PB, Ritchie JK, Hawley PR, Bartram CI, Lennard-Jones JE (1984) Management of enterocutaneous fistulas: a review of 132 cases. Br J Surg 71:293–296PubMed
Metadata
Title
Surgical management of entero and colocutaneous fistulae in Crohn’s disease: 17 year’s experience
Authors
Lisa S. Poritz
G. Alessandra Gagliano
Robin S. McLeod
Helen MacRae
Zane Cohen
Publication date
01-09-2004
Publisher
Springer-Verlag
Published in
International Journal of Colorectal Disease / Issue 5/2004
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-004-0580-x

Other articles of this Issue 5/2004

International Journal of Colorectal Disease 5/2004 Go to the issue

Announcements

September 2004